Company news
Eli Lilly and Co.’s highly anticipated cholesterol drug passed a “futility analysis,” allowing it to complete a critical Phase 3 study in patients, according to Reuters. The drug, called evacetrapib, is designed to boost "good" HDL cholesterol while lowering "bad" LDL cholesterol. An independent panel of scientific advisers recommended that the clinical trial of the […]
